GlassScriptPhysician profile
Robert K Brummeler
NPI 1831205806
$5,118.10
in general payments reported to CMS, 2019-2025
47 companies · $938 in 2025
The $938 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $441 · 2021: $792 · 2022: $1,066 · 2023: $845 · 2024: $623 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.78 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $373.38 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $347.51 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $285.32 | 2020-2022 | |
| Axsome Therapeutics, INC. | $242.17 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Jazz Pharmaceuticals INC. | $234.70 | 2019-2024 | Xywav |
| Allergan, INC. | $220.57 | 2019-2020 | |
| Novo Nordisk INC | $201.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $155.37 | 2021-2023 | Qelbree |
| Pfizer INC. | $140.48 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.68 | 2021-2023 | Trintellix |
| Xeris Pharmaceuticals, INC. | $133.58 | 2021-2022 | |
| Exact Sciences Corporation | $132.16 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $117.99 | 2022 | |
| Dexcom, INC. | $114.25 | 2020-2024 | Dexcom G6 Transmitter |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brummeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.